CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
Multiple Myeloma|Plasma Cell Leukemia
BIOLOGICAL: CT0594CP
Safety and tolerabilitydose limiting toxicity, Safety and tolerability: dose limiting toxicity \[Time Frame: 21-28 days post administration of CT0594CP \], 21-28 days
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia